Home  »  Trendy Stocks   »  Vascular Biogenics Ltd. (VBLT) stock gains in the ...

Vascular Biogenics Ltd. (VBLT) stock gains in the pre-market session. Why is it so?

Vascular Biogenics Ltd. (VBLT) stock declined by 7.29% at the last trading close whereas the VBLT stock rises in the pre-market by 1.12% as of this writing. VBL Therapeutics, formerly Vascular Biogenics, is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of first-in-class therapies for cancer and immune/inflammatory indications.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


VBL has created three platform technologies:

  • A gene-therapy-based technology for treating newly established blood vessels with a cancer focus,
  • An antibody-based platform focusing MOSPD2 for anti-inflammatory and immuno-oncology applications, and the Lecinoxoids,
  • A group of small molecules for immune-related indications.

What is happening?

Today, VBLT confirmed the completion of its underwritten public offering of 6,901,790 ordinary shares, as well as pre-funded options to buy 8,050,000 ordinary shares in an underwritten public offering, at a public price of $1.90 per ordinary share and $1.89 per pre-funded warrant, to some holders. The pre-funded warrants enable holders who are restricted from owning VBLT shares above a defined ownership level (such as 4.99 percent or 19.99 percent) to invest additional funds. In fact, pre-funded warrants are the same as common stock without voting rights. VBL Therapeutics sold all of the shares in the offering.


Before deducting underwriting incentives and commissions, as well as VBL Therapeutics’ sales costs, the Company received nearly $28.3 million in gross proceeds from the public offering. The net proceeds from the sale will be used by VBL Therapeutics for working capital and other general corporate purposes.

The offering’s bookrunning manager was Guggenheim Securities, LLC. Oppenheimer & Co. Inc. was also a joint bookrunner on the deal. Co-managers were Roth Capital Partners and JonesTrading Institutional Services LLC.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Biotech Stocks to Buy for Sep-2021

Biotechnology (biotech) refers to the use of microbes and cellular biology in health-related research and development. It is not just therapies that biotechnology companies develop.




Download Free eBook For


100% free. stop anytime no spam